Trending Now
Reason why ReShape Lifesciences Stock (RSLS) is surging
ReShape Lifesciences Stock More than doubled and last traded at $17.04+10.74 (+170.48%). However, the stock lost quite a bit of steam after...
1606 Corp (CBDW) Expands into Artificial Intelligence with the Introduction of...
The realm of artificial intelligence has been present for a while, yet it garnered heightened attention with the launch of ChatGPT and...
1606 Corp ($CBDW) Preps for Global Launch of Cutting-Edge ChatCBD AI-Driven...
1606 Corp. (OTC Pink: CBDW) is gearing up for the global launch of ChatCBD, an advanced AI-driven online merchandising technology set to debut...
Popular News
MacroGenics Inc. (NASDAQ:MGNX) Reports Its Q3 Financial Results and Clinical Updates...
MacroGenics Inc. (NASDAQ:MGNX) has reported its Q3 2020 financial results and provided its corporate progress update.
MacroGenics advancing three programs
Scott Koenig, the company's CEO...
MAKE IT MODERN
LATEST REVIEWS
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Reports Topline Results Of AT-GAA In Phase...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted topline results in treating LOPD (Late-onset Pompe disease) using its AT-GAA in phase 3, 52-week clinical trial. The US...
MAKE IT MODERN
PERFORMANCE TRAINING
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Substantial Progress In Improving Lives Of Patients With Cancer...
Karyopharm Therapeutics Inc (NASDAQ:KPTI) achieved significant progress in making cancer patients’ lives better with the receipt of FDA approval for its drug – XPOVIO.
Approval...
FibroGen Inc. (NASDAQ:FGEN) Reports Revenue Of $44 Million In Q3 Boosted By Roxadustat Sales...
FibroGen Inc. (NASDAQ:FGEN) has announced its Q3 2020 financial results with strong Roxadustat net sales in China of $22.7 million and also provided corporate...
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Announces Q3 2021 Financial Results And Updates On Expansion...
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) has announced financial results for the quarter ending September 30, 2021, and offered a business update.
Corvus ended Q3 2021...
Outlook Therapeutics Inc (NASDAQ:OTLK) Finalizes Patient Enrollment In Its NORSE 2 Clinical Study Evaluating...
Outlook Therapeutics Inc (NASDAQ:OTLK) recently revealed that it completed the enrollment of patients that will participate in the NORSE 2 clinical trial for ONS-5010...
FDA Issues Positive Opinion On Citius Pharmaceuticals Inc.‘s (NASDAQ:CTXR) Proposed Mino-Lok Therapy Catheter Compatibility...
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) has announced that the FDA has given a positive opinion regarding its proposed plan of studying catheter compatibility for its...
MAKE IT MODERN
